Read our recap of some of the biggest FDA-related stories that impacted cardiology in the last month.

According to data submitted to the FDA, the platform has been linked to an accuracy of 90%, sensitivity of 87.8% and specificity of 83%.

Juan Granada, MD, president and CEO of the Cardiovascular Research Foundation (CRF), shares his thoughts on two key areas of technology advancements in cardiovascular imaging and neuro-interventional care for stroke.

The group will examine data from approximately 1,600 patients, focusing on the relationship between the heart and the aorta. 

Researchers noted that these changes could potentially be attributed to the way in which marijuana is consumed in comparison to tobacco cigarettes, noting that smoking marijuana typically involves a “full inhalation with a sustained Valsalva maneuver.”

James Udelson, MD, an investigator involved with the PRECISE trial, explained how patient outcomes were improved by 70% from the current standard of care.

The group—which includes engineers, cardiologist, radiologists and other specialists—will attempt to perform a robotic-controlled left atrial appendage occlusion (LAAO) on a patient inside an MRI scanner.